The historical rank and industry rank for Barinthus Biotherapeutics's PB Ratio or its related term are showing as below:
STU:2AB'
s PB Ratio Range Over the Past 10 Years
Min: 0.22 Med: 0.42 Max: 2.21
Current: 0.42
During the past 7 years, Barinthus Biotherapeutics's highest PB Ratio was 2.21. The lowest was 0.22. And the median was 0.42.
STU:2AB's PB Ratio is ranked better than 96.26% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs STU:2AB: 0.42
During the past 12 months, Barinthus Biotherapeutics's average Book Value Per Share Growth Rate was -43.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -34.40% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Barinthus Biotherapeutics was -21.90% per year. The lowest was -34.40% per year. And the median was -28.15% per year.
Back to Basics: PB Ratio
Barinthus Biotherapeutics (STU:2AB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Barinthus Biotherapeutics PB Ratio Related Terms
Barinthus Biotherapeutics PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Barinthus Biotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Barinthus Biotherapeutics (STU:2AB) has a PB Ratio of 0.40 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Barinthus Biotherapeutics and its competitors. This is near median its historical median of 0.42. Over the past decade, Barinthus Biotherapeutics' PB Ratio has ranged from 0.22 to 2.21. According to the industry distribution chart, Barinthus Biotherapeutics ranks #46 out of 1229 companies in the Biotechnology industry, placing it in the top 3.7%.
Is Barinthus Biotherapeutics' PB Ratio too high?
Barinthus Biotherapeutics' current PB Ratio of 0.40 is near median its 10-year median of 0.42. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 2.21. The Biotechnology industry median PB Ratio is 2.87. Barinthus Biotherapeutics' value of 0.40 is 86.1% below this industry median. Based on the distribution chart, Barinthus Biotherapeutics ranks #46 out of 1229 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' PB Ratio compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #46 out of 1229 companies for PB Ratio. This places Barinthus Biotherapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.87. Barinthus Biotherapeutics' value of 0.40 is 86.1% below this benchmark. Historically, Barinthus Biotherapeutics' own PB Ratio has ranged from 0.22 to 2.21 over the past decade. While the company's 10-year median is 0.42 vs. the industry median of 2.87, Barinthus Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Barinthus Biotherapeutics's current PB Ratio of 0.40 is 86.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current PB Ratio is 0.40, which is near median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current PB Ratio of 0.40. The stock's GF Value™ is €0.94, compared to a current price of €0.57 — trading 39.9% below its estimated fair value. The current PB Ratio is 0.40, which is near median its 10-year median of 0.42 and 86.1% below the Biotechnology industry median of 2.87. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current PB Ratio is 0.40 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.57 is trading 39.9% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
PB Ratio: 0.40 (near median its 10-year median of 0.42)
GF Value™: €0.94 vs. price of €0.57 (39.9% below fair value)
Industry Position: 86.1% below the Biotechnology median (#46 of 1229)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
